All shareholders in existence as of May 17, 2024 will be eligible to vote.
Final votes must be cast by 11:59pm ET on July 12, 2024.
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW'”) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, invites shareholders to actively participate in its next special meeting of stockholders to be held on July 15, 2024 at 10:00 a.m. (Eastern Time).
The Board of Directors has emphasized the importance of shareholder voting, in particular CThe Company will achieve its goal of passing the three proposals set forth and described in its definitive proxy statement filed on June 26, 2024. The Company encourages shareholders of record on the record date of May 17, 2024 to vote, even if they do not own shares.
If we are unable to secure the number of votes necessary to achieve our goal of passing these three proposals, we may be materially hindered in our ability to conduct our significant business and limit our ability to operate successfully in the future and may be prevented from conducting significant business matters, including: (1) increasing the number of authorized shares of our common stock if necessary for future trading of our stock, (2) consolidating our common stock at up to a ratio of 8 for 1, at our discretion, if necessary to maintain our Nasdaq listing, and (3) issuing securities in a private offering representing a maximum discount of not more than 20% below the market price of our common stock.
The passage of the above three proposals will be of great significance to the Company in carrying out its business plans. The Board of Directors believes that passing these proposals is in the best interest of the Company, and would therefore ask all shareholders to support these proposals.
To change your vote or change your vote:
Stockholders of record as of May 17, 2024 may vote or change their vote by following the instructions in the proxy materials they receive by email or mail on or about June 26, 2024. If you have not received or cannot find your proxy materials, please contact your broker or the Company at (631) 574-4436 or info@sharpstechnology.com to obtain a proxy control number.
How do I vote? Will my shares be voted if I don’t vote?
If you are registered as a shareholder, there are three ways you can vote.
| (1) | On the Internet translation: 24 hours a day, 7 days a week, until 11:59 p.m. ET on July 12, 2024 (please have your 16-digit shareholder control number, found in your proxy statement, ready to access the website). | |
| (2) | Toll-free at 1-800-690-6903 by 11:59 p.m. Eastern Time on July 12, 2024 (please have your 16-digit shareholder control number, found on your proxy statement, ready when you call); or | |
| (3) | Online during a special meeting www.virtualshareholdermeeting.com/STSS2024SMYou will need your 16-digit shareholder control number, which appears on your proxy card, to vote online during the Special General Meeting. | |
Can I change or revoke my power of attorney?
If you have provided us with a power of attorney, you may change or revoke your power of attorney at any time before 11:59 p.m. Eastern Time on July 12, 2024. You may change or revoke your power of attorney in any of the following ways:
- If you received a power of attorney, sign a new power of attorney that is dated after the previous power of attorney and submit it as instructed above.
- Follow the instructions above to re-vote online or by phone.
- Notify the company secretary in writing prior to the EGM that you have revoked your proxy.
- Attend the Special Meeting and vote online. Merely attending the Special Meeting online will not revoke any proxy you may have submitted previously. You must expressly request that your proxy be revoked at the Special Meeting.
The most recent vote will be counted, whether it is by phone, internet or proxy card.
Your proxy will be voted in accordance with your instructions. If you do not vote by internet, telephone or by returning a signed proxy, your designated shares will not be voted unless you attend the special meeting virtually and vote online. If you vote by internet or telephone and do not specify contrary voting instructions, your designated shares will be voted in accordance with the recommendation of our board of directors with respect to all matters and in accordance with the discretion of the proxy holder with respect to any other matters properly referred to the meeting or any adjournment, continuation or postponement thereof. Similarly, if you sign and submit your proxy without any designation, your designated shares will be voted in accordance with the recommendation of our board of directors with respect to all matters and in accordance with the discretion of the proxy holder with respect to any other matters properly referred to the meeting or any adjournment, continuation or postponement thereof. We are not aware of any other matters that may be considered at the special meeting.
Voting will close on July 12, 2024 at 11:59pm ET.
I urge you to vote today.
About Sharps Technology
Sharps Technology is an innovative medical device and pharmaceutical packaging company providing patented, best-in-class smart safety syringe products to the healthcare industry. The company’s product line is focused on providing waste minimization capabilities that incorporate syringe technology that uses both passive and active safety features. Sharps also offers products engineered with specialized copolymer technology to support the prefilled syringe market segment. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand manufacturing capabilities in the United States. For more information, please visit www.sharps.com/. home page.
Forward-Looking Statements:
This press release contains “forward-looking statements.” Forward-looking statements reflect our current views with respect to future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “positioned” or the negative of these terms and similar expressions as they relate to us or our management identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release regarding our business strategy, future operating results and liquidity, and outlook for capital resources. Forward-looking statements are based on current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual results may differ materially from those contemplated in the forward-looking statements. They are not statements of historical fact or guarantees of future performance. You are therefore cautioned not to place any reliance on these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, our ability to finance our continuing operations, our ability to protect our intellectual property rights, the impact of infringement lawsuits or other litigation brought against us, competition from other providers and products, our ability to develop and commercialize products and services, changes to government regulations, our ability to complete financing transactions, and other factors related to our industry, business, and operating results. Actual results may differ materially from what was anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause actual results to differ may arise from time to time, and it is impossible to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. We undertake no obligation to update forward-looking statements to reflect events or circumstances that may occur after the date of this release.
contact address:
Sharps Technology Co., Ltd.
Dave Gentry
Red Chip Companies Inc.
1-800-Red Tip (733-2447)
or 407-644-4256
inquiry
